Antisense therapeutics using synthetic oligodeoxynucleotides (ODNs) are currently being evaluated in clinical trials for cancer, inflammation, and viral diseases. These macromolecules afford a unique opportunity to treat disease at the molecular level. The specificity of these compounds is derived from the genetic code and Watson-Crick base pairing, utilizing an antisense paradigm for the inhibition of translation and the regulation of protein expression. Currently, most antisense ODNs in development contain a phosphorothioate (P=S) backbone. Additional modifications primarily involve the 2' position on the ribose or modification of the nucleotide linkages of the backbone. To date, no toxicities in animal models appear related to inhibition of the pharmacologic target, rather toxicities induced by P=S ODNs appear similar and are independent of pharmacologic target. In general, toxicities correlate well with pharmacokinetic or tissue distribution parameters. In primates, the primary acute effects are associated with complement activation and the systemic effects associated with accumulation of high concentrations of P=S ODNs in the kidneys. In rodents, the primary effect is an immune stimulation characterized by splenomegaly, lymphoid hyperplasia, and mononuclear cell infiltrates in multiple tissues. At extraordinarily high doses (15-50 times the targeted clinical doses), hepatocellular and renal tubular degeneration are evident in rodents. Second generation antisense compounds, new routes of administration, and new formulations appear to broaden and improve the application of antisense technology.
Agrawal S., Zhang X., Lu Z. Zhao H., Tamburin JM, Yan J., Cai H., Diasio RG, Habus I., Jlang Z., Iyer RP, Yu D., and Zhang R. (1995). Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration . Biochem. Pharmacol.50: 571-576.
2.
Altmann KH, Fabbro D., Dean NM, Geiger T., Monia BP, Muuler M., and Nicklin P. (1996). Second-generation antisense oligonucleotides: Structure-activity relationships and the design of improved signal transduction inhibitors. Biochem. Soc. Trans.24: 630-637.
3.
Bennett CF (1998). Antisense oligonucleotides: Is the glass half full or half empty?Biochem. Pharmacol.55: 9-19.
4.
Bennett CF, Kornbrust D., Henry S., Stecker K., Howard R., Cooper S., Dutson S., Hall W., and Jacoby HI (1997). An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J. Pharmacol. Exp. Ther.280: 988-1000.
5.
Bennett CF, Zuckerman JE, Kornbrust D., Sasmor H., Leeds JM, and Crooke ST (1996). Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid . J. Controlled Release41: 121-130.
Crooke ST (1995). Oligonucleotide therapeutics. In: Burger's Medicinal Chemistry and Drug Discovery, Vol. 1, 5th ed., ME Wolff (ed). Wiley and Sons, New York, pp. 863-900.
8.
Crooke ST, Graham MJ, Zuckerman JE, Brooks D., Conklin BS, Cummins LL, Greig MJ, Guinosso CJ, Kornbrust D., Manoharan M., Sasmor HM, Schleich T., Tivel KL, and Griffey RH (1996). Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther.277: 923-937.
9.
Dean NM and Griffey RH (1997). Identification and characterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Dev.7: 229-233.
10.
Dean NM and McKay R. ( 1994). Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides . Proc. Natl. Acad. Sci. USA91: 11762-11766.
11.
Diamantstein T., Wagner B., Beyse I., Odenwald MV, and Schultz G. (1971). Stimulation of humoral antibody formation by polyanions. II. The influence of sulfate esters of polymers on the immune response in mice. Eur. J. Immunol.1: 340-343.
12.
Galbraith WM , Hobson WC, Giclas PC, Schechter PJ, and Agrawal S. (1994). Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev.4: 201-206.
13.
Geary RS, Leeds JM, Fitchett J., Burckin T., Troung L., Spainhour C., Creek M., and Levin AA (1997). Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab. Dispos.25: 1272-1281.
14.
Geary RS, Leeds JM, Henry SP, Monteith DM, and Levin AA (1997). Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides . Anti-Cancer Drug Des. 12: 383-394.
15.
Griffey RH, Lesnik E., Frier S., Sanghvi YS, Teng K., Kawasaki A., Guinoso C., Wheeler P., Mohan V., and Cook PD (1994). New twists on nucleic acids: Structural properties of modified nucleosides incorporated into oligonucleotides. In Carbohydrate Modifications in Antisense Research, Vol. 580, YS Sanghvi and PD Cook (eds). American Chemical Society, Washington, D.C., pp. 212-224.
16.
Henry SP, Bolte H., Auletta C., and Kornbrust DJ (1997). Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology120: 145-155.
17.
Henry SP, Giclas PC, Leeds J., Pangburn M., Auletta C., Levin AA, and Kornbrust DJ (1997). Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action. J. Pharmacol. Exp. Ther.281: 810-816.
18.
Henry SP, Grillone LR, Orr JL, Brunner RH, and Kornbrust DJ (1997). Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats. Toxicology116: 77—88.
19.
Henry SP, Monteith D., and Levin AA (1997). Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicologic properties of phosphorothioate oligodeoxynucleotides . Anti-Cancer Drug Des. 12: 395-408.
20.
Henry SP, Novotny W., Leeds J., Auletta C., and Kornbrust DJ (1997). Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev.7: 503—510.
21.
Henry SP, Taylor J., Midgley L., Levin AA, and Kornbrust DJ (1997). Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev.7: 473-481.
22.
Homan ER, Zendzian RP, Schott LD, Levy HB, and Adamson RH (1972). Studies on poly I: C toxicity in experimental animals. Toxicol. Appl. Pharmacol.23: 579-588.
23.
Horner MJ, Monteith DK, Gillett NA, Butler M., Henry SP, Bennett CF, and Levin AA (1997). Evaluation of the renal effects of phosphorothioate oligonucleotides in monkeys. Fundam. Appl. Toxicol.36(suppl.): 147 (abstract).
24.
Kuramoto E., Yano O., Kimura Y., Baba M., Makino T., Yamamoto S., Yamamoto T., Kataoka T., and Tokonaga T. (1992). Oligonucleotide sequences required for natural killer cell activation. Jpn. J. Cancer Res.83: 1128-1131.
25.
Leonetti C. , Dagnano I., Lozupone F., Valentini A., Geiser T., Zon G., Calabretta B., Citro G., and Zupi G. (1996). Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J. Natl. Cancer Inst.88: 419-429.
26.
Ma L. and Calvo F. (1996). Recent status of the antisense oligonucleotide approaches in oncology. Fundam. Clin. Pharmacol.10: 97-115.
27.
Mandiyan S. , Schumacher C., Cioffi C., Sharif H., Yuryev A., Lappe R., Monia B., Hanson S., Goff S., and Wennogle L. ( 1997). Molecular and cellular characterization of baboon C-Raf as a target for antiproliferative effects of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev.7: 539-548.
28.
Manoharan M. , Tivel KL, Condon TP, Andrade LK, Barber-Peoch I., Inanmati G., Shah S., Mohan V., Graham MJ, Bennett CF, Crooke ST, and Cook PD (1997). Conjugated antisense oligonucleotides. Nucleosides Nucleotides16: 1129-1138.
29.
Manza LL, Butler MM, Bennett CF, Levin AA, de Peyster AA, and Monteith DK (1997). Renal toxicity of phosphorothioate oligonucleotides in rats. Fundam. Appl. Toxicol.36(suppl.): 147 (abstract).
30.
Monia BP, Sasmor H., Johnston JF, Freier SM, Lesnik EA, Muller M., Geiger T., Altmann KH, Moser H., and Fabbro D. (1996). Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human c-raf kinase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. Sci. USA93: 15481-15484.
31.
Monteith DKGeary RSLeeds JM, Johnston J.Monia BP, and Levin AA (1998). Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Toxicol. Sci.46: (in press).
32.
Monteith DK , Henry SP Howard RB, Flournoy S., Levin AA, Bennett CF, and Crooke ST (1997). Immune stimulation—A class effect of phosphorothioate oligodeoxynucleotides in rodents. AntiCancer Drug Des. 12: 421-432.
33.
Phillips JA , Craig SJ, Bayley D., Christian RA, Geary R., and Nicklin PL (1997). Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration . Biochem. Pharmacol.54: 657-668.
34.
Pisetsky DS and Reich CF (1994). Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Life Sci.54: 101-107.
35.
Sarmiento UM , Perez JR, Becker JM, and Ramaswamy N. (1994). In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res. Dev.4: 99-107.
36.
Shimada S., Yano O., and Tokunaga T. (1986). In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG. Jpn. J. Cancer Res.77: 808-816.
37.
Stepkowski SM, Tu Y., Condon TP, and Bennett CF (1994). Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J. Immunol.153: 5336-5346.
38.
Tokunaga T. , Yamamato S., and Namba K. (1988). A synthetic single-stranded DNA, poly (dG, dC), induces interferon-α/β and -γ augments natural killer activity, and suppresses tumor growth. Jpn. J. Cancer Res.79: 682-686.
39.
Yamamoto T. , Yamamoto S., Kataoka T., and Tokunaga T. (1994). Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Antisense Res. Dev.4: 119-122.
40.
Yazaki T., Ahmad S., Chahlavi A., Zylber-Katz E., Dean NM, Rabkin SD, Martuza RL and Glazer RI (1996). Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide . Mol. Pharmacol.50: 236-242.
